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Opioids are intensely addictive, and cessation of their chronic use is associated with
a highly aversive withdrawal syndrome. A cellular hallmark of withdrawal is an opioid
sensitive protein kinase A-dependent increase in GABA transporter-1 (GAT-1) currents in
periaqueductal gray (PAG) neurons. Elevated GAT-1 activity directly increases GABAergic
neuronal excitability and synaptic GABA release, which will enhance GABAergic inhibition
of PAG output neurons. This reduced activity of PAG output neurons to several
brain regions, including the hypothalamus and medulla, contributes to many of the
PAG-mediated signs of opioid withdrawal. The GABAB receptor agonist baclofen reduces
some of the PAG mediated signs of opioid withdrawal. Like the opioid receptors the
GABAB receptor is a Gi/Go coupled G-protein coupled receptor. This suggests it could
be modulating GAT-1 activity in PAG neurons through its inhibition of the adenylyl
cyclase/protein kinase A pathway. Opioid modulation of the GAT-1 activity can be detected
by changes in the reversal potential of opioid membrane currents. We found that when
opioids are reducing the GAT-1 cation conductance and increasing the GIRK conductance
the opioid agonist reversal potential is much more negative than Ek . Using this approach
for GABAB receptors we show that the GABAB receptor agonist, baclofen, does not couple
to inhibition of GAT-1 currents during opioid withdrawal. It is possible this differential
signaling of the two Gi/Go coupled G-protein coupled receptors is due to the strong
compartmentalization of the GABAB receptor that does not favor signaling to the adenylyl
cyclase/protein kinase A/GAT-1 pathway. This highlights the importance of studying the
effects of G-protein coupled receptors in native tissue with endogenous G-protein coupled
receptors and the full complement of relevant proteins and signaling molecules. This study
suggests that baclofen reduces opioid withdrawal symptoms through a non-GAT-1 effector.
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INTRODUCTION
Opioids are intensely addictive, and cessation of their chronic
use is associated with a withdrawal syndrome consisting of
severe early physical symptoms and late features such as crav-
ing. Relapse into drug-taking behaviors often occurs as a result
of this withdrawal syndrome (Mattick and Hall, 1996; Williams
et al., 2001), which is thought to result from neuronal adapta-
tions that develop to restore homeostasis during chronic opioid
exposure (Himmelsbach, 1943). On cessation of opioid admin-
istration, persistent counteradaptations in critical brain regions
are unmasked and cause the withdrawal syndrome. A rebound
increase of adenylyl cyclase/protein kinase A (PKA) signaling
is one counteradaptation. While opioid agonists acutely inhibit
adenylyl cyclase activity in the brain (Collier and Roy, 1974)
and specifically in the periaqueductal gray (PAG) (Fedynyshyn
and Lee, 1989), there is a compensatory increase in adeny-
lyl cyclase signaling during chronic treatment with morphine
in vitro (Sharma et al., 1975; Avidor-Reiss et al., 1997) and in vivo
(Terwilliger et al., 1991) resulting in rebound hyperactivity of this
cascade during withdrawal. Microinjections of PKA inhibitors
into the PAG attenuate a spectrum of opioid withdrawal behaviors
similar to those induced by microinjections of opioid antago-
nists (Maldonado et al., 1995; Punch et al., 1997). Whilst the
importance of upregulated adenylyl cyclase/PKA during opioid
withdrawal has been appreciated for many years we have only
recently found the cellular target of PKA that results in with-
drawal symptoms (Bagley et al., 2005b, 2011). We found that
elevated PKA activity during withdrawal increases GABA trans-
porter 1 (GAT-1) currents in PAG neurons (Bagley et al., 2005b).
Elevated GAT-1 activity directly depolarizes and thus hyperexcites
GABAergic PAG neurons and nerve terminals, which presumably
enhances GABAergic inhibition of PAG output neurons (Bagley
et al., 2005b). This reduced activity of PAG output neurons to
several brain regions, including the hypothalamus and medulla,
results in opioid withdrawal signs (Bagley et al., 2011).
Opioid receptors are Gi/Go coupled G-protein coupled recep-
tors that inhibit adenylyl cyclase through their Gα subunit. The
GABAB receptor is another Gi/Go coupled G-protein coupled
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receptor (Bettler et al., 2004) that inhibits adenylyl cyclase activity
(Gerber andGähwiler, 1994; Kuner et al., 1999; Bettler et al., 2004;
Vanhoose et al., 2004; Connelly et al., 2013). GABAB receptors
are expressed in almost all PAG neurons (Chieng and Christie,
1996; Margeta-Mitrovic et al., 1999; Bagley et al., 2005a). The
GABAB receptor agonist baclofen reduces some PAG mediated
signs of opioid withdrawal in humans (Ahmadi-Abhari et al.,
2001; Tyacke et al., 2010) and animal models (Bexis et al., 2001;
Tyacke et al., 2010) and is used in drug cocktails for treat-
ment of opioid withdrawal (Collis, 2008). Given the similari-
ties in coupling and the therapeutic utility of GABAB receptor
agonists, in this study we ask whether GABAB receptor ago-
nists act like opioids to reduce GAT-1 activity during opioid
withdrawal.
MATERIALS AND METHODS
CHRONIC TREATMENT WITH MORPHINE
Morphine dependence was induced by a series of subcutaneous
injections of sustained-release morphine suspension into male
C57B16/J mice (300mg/kg morphine base) as in previous exper-
iments (Bagley et al., 2005b, 2011). Injections (0.1–0.2ml) were
made under light halothane anesthesia on days 1, 3, and 5, and
mice were used for experiments on days 6 or 7.Morphine base was
suspended in 0.1ml mannide mono-oleate (Arlacel A, Sigma),
0.4ml light liquid paraffin and 0.5ml 0.9% w/v NaCl in water.
Vehicle-treated mice were injected on the same schedule with
morphine-free suspension.
TISSUE PREPARATION AND RECORDINGS
PAG slices (220–250μm) were cut from 4- to 6-week-old mice
and were maintained at 34◦C in a submerged chamber con-
taining physiological saline (ACSF) equilibrated with 95% O2
and 5% CO2 and were later transferred to a chamber super-
fused at 2ml/min with ACSF (34◦C) for recording. The stan-
dard ACSF contained 126mM NaCl, 2.5mM KCl, 1.4mM
NaH2PO4, 1.2mM MgCl2, 2.4mM CaCl2, 11mM glucose, and
25mM NaHCO3. Brain slices from both morphine-dependent
and vehicle-treated mice were maintained in vitro in ACSF con-
taining 5μM morphine. Unless otherwise stated, slices were
spontaneously withdrawn by incubation in morphine-free ACSF
for at least 1 h before an experiment. CGP55845 was a gift from
Ciba Ltd (Basel, Switzerland).
PAG neurons were visualized using infra-red Nomarski
optics. Perforated patch recordings were made using patch elec-
trodes (4–5m) filled with 120mM K acetate, 40mM HEPES,
10mM EGTA, 5mM MgCl2, with 0.25mg/ml Pluronic F-127,
0.12mg/ml amphotericin B (pH 7.2, 290 mosmol/l). Liquid junc-
tion potentials for K acetate internal solution of −8mV with
ACSF were corrected. Series resistance (<25M) was com-
pensated by 80% and continuously monitored. During perfo-
rated patch recordings, currents were recorded using a Axopatch
200A amplifier (Axon Instruments), digitized, filtered (at 2 kHz),
and then acquired (sampling at 10 kHz) in pClamp (Axon
Instruments) or using Axograph Acquisition software (Axon
Instruments).
All pooled data are expressed as mean ± s.e.m. We tested for
significance using the unpaired Student’s t-test.
RESULTS
In PAG neurons, withdrawal from chronic morphine-treatment
stimulates a protein kinase A-dependent increase of the GAT-1
cation conductance (Bagley et al., 2005b, 2011). The increased
GAT-1 activity is sensitive to opioid inhibition and therefore
during opioid withdrawal it can be detected by changes in the
opioid agonist met-enkephalin (MENK) current reversal poten-
tial. When MENK is reducing the GAT-1 cation conductance
and increasing the GIRK conductance the MENK reversal poten-
tial will be much more negative than Ek (Bagley et al., 2005b).
Superfusion of (MENK) produced an outward current in 4 out
of 6 PAG neurons voltage clamped at −56mV in slices from
vehicle-treated mice (30 ± 4 pA, n = 4, Figure 1A). In neurons
from vehicle-treated mice the ME current reversed polarity at
a potential of −109 ± 4mV (n = 4, Figures 1B,D), close to the
potassium reversal potential (Ek,−103mV) in these conditions as
we have previously reported in mice (Bagley et al., 2005b, 2011).
In neurons from chronic morphine-treated mice, the MENK-
induced current reversed in only 2 of 5 cells (Figure 1C). In
the neurons where the MENK current did not reverse polarity
at the most negative potential tested, the reversal potentials was
assigned a value of−136mV, a conservative approach we adopted
in previous studies to deal with technical inability to determine
extremely negative reversal potentials (Bagley et al., 2005b, 2011).
The nominal reversal potential for the 5 cells was −1.8 ± 4mV
(Figures 1C,D) that is significantly more negative than neurons
from vehicle mice (p = 0.034, Students t-test, Figure 2E). We
have previously shown that in the presence of the GAT-1 inhibitor,
NO-711, results in ME currents that reversed polarity close to the
value for MENK currents in neurons from vehicle-treated mice
(Bagley et al., 2005b, 2011).
Superfusion of the GABAB receptor agonist baclofen (10μM)
produced an outward current in all 8 PAG neurons volt-
age clamped at −56mV in slices from vehicle-treated mice
(31 ± 5 pA, n = 14, Figure 2A). In neurons from vehicle treated
mice the baclofen current reversed polarity at a potential
of −116 ± 5mV (n = 8, Figures 2B,D,E), close to Ek in these
conditions (−103mV). In neurons from morphine-treated mice
the baclofen-induced outward current (30 ± 5 pA, n = 17)
reversed polarity (−117 ± 2mV, n = 17, Figures 2C–E) close to
Ek (−103mV) and at a similar membrane potential to cells from
vehicle-treated mice (p = 0.71 Students t-test).
DISCUSSION
A cellular hallmark of withdrawal in PAG is protein kinase A-
dependent increases in GAT-1 currents (Bagley et al., 2005b,
2011). This study showed that even though the opioid receptors
and GABAB receptor are both Gi/Go coupled G-proteins cou-
pled receptors occurring in the same neurons GABAB receptors
are unable to couple via PKA to the additional GAT-1 conduc-
tance. The selectivity is not due to the GABAB receptor and opioid
receptors being located in different neurons. Whilst only two
thirds to three quarters of PAG neurons are opioid sensitive, as
shown in this study and previously (Vaughan et al., 2003), almost
all PAG neurons are sensitive to GABAB receptor agonists (97% in
this study and Chieng and Christie, 1995). In this study we only
included neurons that were sensitive to both agonists. GABAB
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FIGURE 1 | Opioid receptors simultaneously couple to a potassium
conductance and a GAT-1 conductance. (A) Example trace of currents
from a neuron voltage clamped at −56mV (drug superfusion shown by
bars). MENK (30μM) induced an outward current in neuron from a
morphine-treated mouse. (B,C) Currents produced by voltage steps
from −56mV to −136mV in −10mV increments in a neuron from (B) a
vehicle-treated mouse and (C) a morphine-treated mouse before (left) and
during MENK (30μM) application (right). (D) Subtracted current-voltage
relationships for MENK (current in MENK—current during control
conditions). Reversal potentials were determined at the point where they
cross the abscissa. The MENK current reversed polarity near EK in neurons
from vehicle-treated (n = 4), but not in neurons from morphine-treated
mice (n = 5).
receptor agonists inhibit adenylyl cyclase after expression in cell
lines (Kuner et al., 1999; Bettler et al., 2004) and in brain tis-
sue (Gerber and Gähwiler, 1994; Vanhoose et al., 2004) and there
are examples where this inhibition of adenylyl cyclase regulates
ionic conductances in several different brain regions (Gerber and
Gähwiler, 1994; Connelly et al., 2013). Therefore, if the receptors
FIGURE 2 | GABAB receptors do not couple to a GAT-1 conductance. (A)
Example trace of currents from a neuron voltage clamped at −56mV (drug
superfusion shown by bars). Baclofen (10μM) induced an outward current
in a neuron from a morphine-treated mouse. (B,C) Currents produced by
voltage steps from −56mV to −136mV in −10mV increments in a neuron
from (B) a vehicle-treated mouse and (C) a morphine-treated mouse before
(left) and during baclofen (10μM) application (right). (D) Subtracted
current-voltage relationships for baclofen (current in baclofen–current during
control conditions). Reversal potentials were determined at the point where
they cross the abscissa. The baclofen current reversed polarity near EK in
neurons from vehicle-treated (n = 8), and morphine-treated mice (n = 17).
(E) Reversal potential of the MENK and baclofen-induced currents in cells
from vehicle-treated and chronic morphine-treated mice. Arrows indicate
that the average current did not reverse polarity at the most negative
potential that could be tested (−136mV). The number of neurons is shown
beside the bar. ∗P-value of 0.034, Students t-test.
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are located on the same neurons and can couple to the adenylyl
cyclase/PKA signaling pathway this suggests that there must be
some sort of compartmentalization that prevents baclofen from
regulating GAT-1 activity. Conversely, compartmentalizationmay
favor opioid receptor regulation of GAT-1.
Like other Gi/Go coupled G-proteins coupled receptors
GABAB receptors can couple to several effectors, including cal-
cium channels, GIRK and adenylyl cyclase. However, GABAB
receptors appear to show greater segregation than other G-protein
coupled receptor signaling and possibly stronger regulation into
nano-signaling complexes. Opioids and GABAB receptors have
previously been shown to differentially couple to their effectors.
This occurs in GABAergic nerve terminals in the PAG. Opioid
receptor activation reduces GABA release from nerve terminals
in the PAG through modulation of a voltage dependent potas-
sium channel where as GABAB receptors do not couple to GABA
inhibition through this mechanism (Vaughan et al., 1997). It
seems likely that, as in this study, both the GABAB receptors
and opioid receptors are expressed on the same GABAergic ter-
minals in the PAG again indicating compartmentalization. This
also occurs outside the PAG. In locus coeruleus neurons both
opioid and α2 receptors inhibit the same population of calcium
channels in these neurons but GABAB receptors inhibit a sep-
arate population of calcium channels in the same cell (Chieng
and Bekkers, 1999). Of all the Gi/Go coupled effects there is evi-
dence that GABAB receptor regulation of AC/PKA activity may be
particularly affected by compartmentalization. GABAB receptor
inhibition of adenylyl cyclase in the hippocampus was stimu-
lation dependent whereas other Gi/Go coupled receptors were
able to inhibit adenylyl cyclase regardless of how it was stimu-
lated (Vanhoose et al., 2004). These differences may be due to
GABAB receptors being localized to nano-signaling complexes
that influence their signaling to different effectors. The influence
of nan-signaling complexes on GABAB receptors on signaling is
evidenced by inclusion of GABAB receptors in nano-signaling
complexes facilitating inhibition of calcium channels but not
inhibition of adenylyl cyclase (Laviv et al., 2011). Further, GABAB
receptors, and especially the splice variants of the GABAB1 recep-
tor, show differential subcellular localization and associations
with protein clusters that alter their coupling to effectors (Vigot
et al., 2006). Therefore, GABAB receptorsmay notmodulate GAT-
1 activity in this study because they are preferentially associated
with proteins or located in regions of the cell that do not favor
inhibition of adenylyl cyclase.Whilst the evidence for strong com-
partmentalization of GABAB receptor signaling is convincing it
is also possible that it is the location/compartmentalization of
the opioid receptors that allows their coupling to GAT-1 activity.
Perhaps opioid receptors are more closely localized to the subcel-
lular region or associated with the adenylyl cyclase/PKA/GAT-1
proteins upregulated by chronic opioid inhibition.
If we want to ask questions about processes occurring in
the brain during particular disease states, as opposed to cell
lines or cultured cells, it is critical that these experiments are
conducted in native tissue. Experiments in native tissue study
endogenous GPCRs with the full complement of relevant proteins
and signaling molecules. In fact the opioid-AC-PKA modula-
tion of GAT-1 was a surprise because the only consensus site
for PKA phosphorylation is extracellular (Guastella et al., 1990)
making it an unlikely candidate for regulation by PKA. Whilst
the effect of PKA activation on the GAT-1 transporter has not
been comprehensively studied, the subcellular location, enzy-
matic activity, and absolute level of GAT-1 is regulated in a
complex inter-related manner by PKC activity, GABA concen-
tration, ionic conditions, tyrosine kinase activity, and the release
protein syntaxin 1A (Beckman and Quick, 1998; Beckman et al.,
1998; Whitworth and Quick, 2001; Quick, 2002). Therefore, it is
likely due to AC/PKA altering GAT-1 activity through an interme-
diary protein not expressed/or active in the cultured cells. Support
for this proposal comes from another study of GAT-1 in brain
tissue showing that AC/PKA activity facilitates GAT-1 transport
by curbing tonic PKC-mediated inhibition of GAT-1 activity and
cell surface expression (Cristóvão-Ferreira et al., 2009). Therefore,
during opioid withdrawal the overshoot in AC/PKA activity in
PAG neurons could be could indirectly increasing GAT-1 activity
through reducing PKC restraints on GAT-1 activity. The results
from this study also show how important it is to conduct exper-
iments in native tissue. We would have predicted that another
Gi/Go coupled GPCR, such as GABAB, that inhibits adenylyl
cyclase (Gerber and Gähwiler, 1994; Kuner et al., 1999; Bettler
et al., 2004; Vanhoose et al., 2004; Connelly et al., 2013) and is
in the same cell as the opioid receptors would have modulated
GAT-1 activity. Although GABAB receptors may modulate GAT-
1 activity under other conditions or in different cells it does not
occur in the PAG neurons important for opioid withdrawal.
The opioid sensitive GAT-1 activity in the PAG during with-
drawal initiates the opioid withdrawal syndrome (Bagley et al.,
2011). The GABAB agonist baclofen reduces some of the signs
of opioid withdrawal (Ahmadi-Abhari et al., 2001; Bexis et al.,
2001; Tyacke et al., 2010) but does not alter the GAT-1 activity.
One possible explanation for this is that an important outcome
of the elevated GAT-1 activity during withdrawal is depolar-
ization of GABA neurons and a resultant increase in synaptic
GABA release. The increased GABA release inhibits PAG output
neurons, changes neurotransmitter release in their target brain
regions and ultimately expression of the withdrawal signs. Whilst
GABAB receptor activation can’t reduce the GAT-1 activity that
drives GABA release it could act to inhibit the excitability of
GABAergic neurons through other mechanisms. Reduced GABA
release could result from inhibition of GABA neuron excitabil-
ity, through activation of GIRK, and inhibition of GABA release
through non-GAT1 effectors. Through this alternative mecha-
nism of inhibiting GABA release it would diminish inhibition of
output neurons and thus withdrawal.
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